Lawrence R Kleinberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11785062/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mutation status and postresection survival of patients with non–small cell lung cancer brain metastasis: implications of biomarker-driven therapy. Journal of Neurosurgery, 2022, 136, 56-66.	1.6	3
2	Utility of expanded anterior column resection versus decompression-alone for local control in the management of carcinomatous vertebral column metastases undergoing adjuvant stereotactic radiotherapy. Spine Journal, 2022, 22, 835-846.	1.3	5
3	A multi-institutional pilot clinical trial of spectroscopic MRI-guided radiation dose escalation for newly diagnosed glioblastoma. Neuro-Oncology Advances, 2022, 4, vdac006.	0.7	14
4	Final Report on Clinical Outcomes and Tumor Recurrence Patterns of a Pilot Study Assessing Efficacy of Belinostat (PXD-101) with Chemoradiation for Newly Diagnosed Glioblastoma. Tomography, 2022, 8, 688-700.	1.8	8
5	Deviation from consensus contouring guidelines predicts inferior local control after spine stereotactic body radiotherapy. Radiotherapy and Oncology, 2022, 173, 215-222.	0.6	11
6	Single- and Multifraction Stereotactic Radiosurgery Dose/Volume Tolerances of the Brain. International Journal of Radiation Oncology Biology Physics, 2021, 110, 68-86.	0.8	164
7	External Validation of the Bone Metastases Ensemble Trees for Survival (BMETS) Machine Learning Model to Predict Survival in Patients With Symptomatic Bone Metastases. JCO Clinical Cancer Informatics, 2021, 5, 304-314.	2.1	7
8	Tumor Control Probability of Radiosurgery and Fractionated Stereotactic Radiosurgery for Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2021, 110, 53-67.	0.8	62
9	Long-Term Results of Gamma Knife Radiosurgery for Glomus Tumors: An Analysis of 32 Patients. Cureus, 2021, 13, e18095.	0.5	0
10	Multiparametric radiomic tissue signature and machine learning for distinguishing radiation necrosis from tumor progression after stereotactic radiosurgery. Neuro-Oncology Advances, 2021, 3, vdab150.	0.7	8
11	Phase II Study of Preoperative Chemoradiotherapy with Oxaliplatin, Infusional 5-Fluorouracil, and Cetuximab Followed by Postoperative Docetaxel and Cetuximab in Patients with Adenocarcinoma of the Esophagus: A Trial of the ECOG-ACRIN Cancer Research Group (E2205). Oncologist, 2020, 25, e53-e59.	3.7	6
12	Tumor Treating Fields: At the Crossroads Between Physics and Biology for Cancer Treatment. Frontiers in Oncology, 2020, 10, 575992.	2.8	30
13	A Prospective Cohort Study of Neural Progenitor Cell-Sparing Radiation Therapy Plus Temozolomide for Newly Diagnosed Patients With Glioblastoma. Neurosurgery, 2020, 87, E31-E40.	1.1	13
14	Potential Clinical Significance of Overall Targeting Accuracy and Motion Management in the Treatment of Tumors That Move With Respiration: Lessons Learnt From a Quarter Century of Stereotactic Body Radiotherapy From Dose Response Models. Frontiers in Oncology, 2020, 10, 591430.	2.8	4
15	Assessing the Effectiveness of Systemic Therapy after Stereotactic Radiosurgery on Cancer Recurrence and All-Cause Mortality. World Neurosurgery, 2019, 129, e572-e581.	1.3	Ο
16	Volume effects in radiosurgical spinal cord dose tolerance: how small is too small?. Journal of Radiation Oncology, 2019, 8, 53-61.	0.7	8
17	Initial SRS for Patients With 5 to 15 Brain Metastases: Results of a Multi-Institutional Experience. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1091-1098.	0.8	89
18	Updated risk models demonstrate low risk of symptomatic radionecrosis following stereotactic		15

radiosurgery for brain metastases. , 2019, 10, 32.

#	Article	IF	CITATIONS
19	Extracranial Abscopal Responses after Radiation Therapy for Intracranial Metastases: A Review of the Clinical Literature and Commentary on Mechanism. Cureus, 2019, 11, e4207.	0.5	7
20	Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system. Oncolmmunology, 2018, 7, e1500108.	4.6	52
21	Clinical evidence for dose tolerance of the central nervous system in hypofractionated radiotherapy. Journal of Radiation Oncology, 2018, 7, 293-305.	0.7	2
22	Re-irradiation for malignant glioma: Toward patient selection and defining treatment parameters for salvage. Advances in Radiation Oncology, 2018, 3, 582-590.	1.2	20
23	Outcomes of Metastatic Brain Lesions Treated with Radioactive Cs-131 Seeds after Surgery: Experience from One Institution. Cureus, 2018, 10, e3075.	0.5	8
24	Progressive Low-Grade Glioma: Assessment of Prognostic Importance of Histologic Reassessment and MRI Findings. World Neurosurgery, 2017, 99, 751-757.	1.3	19
25	A prospective evaluation of hippocampal radiation dose volume effects and memory deficits following cranial irradiation. Radiotherapy and Oncology, 2017, 125, 234-240.	0.6	65
26	Long-term Outcomes With Planned Multistage Reduced Dose Repeat Stereotactic Radiosurgery for Treatment of Inoperable High-Grade Arteriovenous Malformations: An Observational Retrospective Cohort Study. Neurosurgery, 2017, 81, 136-146.	1.1	9
27	The strategy of repeat stereotactic radiosurgery without whole brain radiation treatment for new brain metastases: Outcomes and implications for follow-up monitoring. Practical Radiation Oncology, 2016, 6, 409-416.	2.1	24
28	Controversies in the Therapy of Brain Metastases: Shifting Paradigms in an Era of Effective Systemic Therapy and Longer-Term Survivorship. Current Treatment Options in Oncology, 2016, 17, 46.	3.0	22
29	Stereotactic Radiosurgery: Treatment ofÂBrainÂMetastasis Without Interruption ofÂSystemic Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 95, 735-742.	0.8	37
30	Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Randomized Phase 2 Trial of Neoadjuvant Preoperative Paclitaxel/Cisplatin/Radiation Therapy (RT) or Irinotecan/Cisplatin/RT in Esophageal Adenocarcinoma: Long-Term Outcome and Implications for Trial Design, International Journal of Radiation Oncology Biology Physics, 2016, 94, 738-746.	0.8	16
31	Antiangiogenic Therapies and Extracranial Metastasis in Glioblastoma: A Case Report and Review of the Literature. Case Reports in Oncological Medicine, 2015, 2015, 1-5.	0.3	4
32	Expert Consensus Contouring Guidelines for Intensity Modulated Radiation Therapy in Esophageal and Gastroesophageal Junction Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 92, 911-920.	0.8	112
33	Prognostic factors associated with pain palliation after spine stereotactic body radiation therapy. Journal of Neurosurgery: Spine, 2015, 23, 620-629.	1.7	26
34	The Radiosurgical Treatment of Arteriovenous Malformations: Obliteration, Morbidities, and Performance Status. International Journal of Radiation Oncology Biology Physics, 2011, 80, 354-361.	0.8	40
35	Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. Expert Review of Anticancer Therapy, 2008, 8, 343-359.	2.4	54
36	Repeat stereotactic radiosurgery for high-grade and large intracranial arteriovenous malformations. World Neurosurgery, 2007, 68, 24-34.	1.3	21

#	Article	IF	CITATIONS
37	Clinical Course and Pathologic Findings After Gliadel® and Radiotherapy for Newly Diagnosed Malignant Glioma: Implications for Patient Management. Cancer Investigation, 2004, 22, 1-9.	1.3	72